Endoscopy 2020; 52(S 01): S53
DOI: 10.1055/s-0040-1704164
ESGE Days 2020 oral presentations
Thursday, April 23, 2020 16:30 – 18:00 Stent, seal, stitch. Advanced upper GI Ecocem Room therapeutics
© Georg Thieme Verlag KG Stuttgart · New York

EFFICACY OF INTRAGASTRIC BALLOONS FOR WEIGHT LOSS IN OVERWEIGHT AND OBESE ADULTS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

APST Kotinda
1   University of São Paulo Medical School - Gastrointestinal Endoscopy Unit, São Paulo, Brazil
,
DTH de Moura
1   University of São Paulo Medical School - Gastrointestinal Endoscopy Unit, São Paulo, Brazil
,
IB Ribeiro
1   University of São Paulo Medical School - Gastrointestinal Endoscopy Unit, São Paulo, Brazil
,
S Singh
2   West Virginia University Health Sciences Center, Division of Gastroenterology, Charleston, U S A
,
M Coronel
1   University of São Paulo Medical School - Gastrointestinal Endoscopy Unit, São Paulo, Brazil
,
WM Bernardo
1   University of São Paulo Medical School - Gastrointestinal Endoscopy Unit, São Paulo, Brazil
,
C C Thompson
3   Brigham and Women’s Hospital, Division of Gastroenterology, Hepatology and Endoscopy, Boston, U S A
,
EGH de Moura
1   University of São Paulo Medical School - Gastrointestinal Endoscopy Unit, São Paulo, Brazil
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
23. April 2020 (online)

Auch verfügbar auf
 

Aims More than 1.9 billion adults are overweight, and 650 million are obese globally, and yet these overwhelming statistics continue to rise. Endoscopic bariatric and metabolic therapies (EBMTs) are minimally invasive procedures developed to complement the obesity treatment. Intragastric balloons (IGB) are the most widely used EBMT, but studies have shown variable weight loss outcomes. We aimed to evaluate the efficacy of IGBs in comparison to lifestyle Interventions alone for weight loss in overweight and obese patients.

Methods The study was conducted in accordance with the PRISMA guidelines. Electronic searches were performed using MEDLINE, EMBASE, Cochrane CENTRAL, and Lilacs/Bireme databases from their dates of inception to November 2019. Only Randomized Controlled Trials (RCTs) were eligible for inclusion. The primary outcomes were the difference in mean percentage of excess weight loss (%EWL) and percentage of total weight loss (%TWL). Absolute weight loss (AWL), body mass index loss (BMIL), final BMI, and final weight were also analyzed.

Results A total of 6520 studies were screened for eligibility. Out of these, 13 RCTs with 1523 patients (859 in the intervention group and 664 in the control group) were finally included in the meta-analysis. The difference in mean %EWL and %TWL at follow up was 17.98% (95%CI 8.37-27.58), and 4.40% (95%CI 1.37-7.43), respectively, which was significantly higher in the IGB group. Similarly, the difference in mean final BMI, final weight, AWL, and BMIL between IGB group and control group as -3.02 (95%CI, -4.53 - -1.51), -5.68 kg (95%CI, -8.92 - -2.43), 6.12 kg (95%CI, 3.80 - 8.44), and 2.13 kg/m2 (95%CI, 0.57 - 3.68), respectively. The BMI range was 27 to 65, and the duration of follow up after IGB varied between 3 months to 8 months.

Conclusions IGB therapy is more effective than lifestyle intervention alone for weight loss in overweight and obese adults.